Announcements Trials
Browse Landscape

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 13Observational 2Expanded_access 1

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 1Neuroendocrine Tumor Grade 3 1

Interventions

Surveys and Questionnaires 8Blood Specimen Collection 7lutetium Lu 177 dotatate 6Surgical Procedures, Operative 6Magnetic Resonance Spectroscopy 6Adrenalectomy 5Observation 4Transurethral Resection of Prostate 3Thyroidectomy 3Positron-Emission Tomography 3Lymph Node Excision 3Data Collection 3telotristat ethyl 2surufatinib 2gallium Ga 68 dotatate 2Somatostatin 2Radionuclide Imaging 2Radiofrequency Ablation 2Everolimus 2Drug Therapy 2Biopsy 2somapacitan 1methyl hydroxyethyl cellulose 1lanreotide 1fluorodopa F 18 1exemestane 1delta 24-sterol reductase 1copper dotatate CU-64 1Whole Body Imaging 1Walking 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × surufatinib × Endocrine × Clear all
NCT07534371 2026-04-16

Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study

West China Hospital

Active not recruiting
500 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05973968 2023-08-04

Surufatinib in G3 Neuroendocrine Tumors

Qilu Hospital of Shandong University

Unknown
32 enrolled
EndocrineNET

Neuroendocrine Tumor Grade 3

Data powered by HemOnc (CC BY 4.0) Colophon âš¡